Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 174

Sort by

Sort Order Select

Journal Articles

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Blood (2024) 143 (2): 139–151.

https://doi.org/10.1182/blood.2022018658

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Blood (2023) 141 (6): 609–619.

https://doi.org/10.1182/blood.2022017866

Published: 2023

Includes: Supplemental data

Journal Articles

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Caroline Diorio, Tiffaney L. Vincent, Tori Fuller, Rawan Shraim, Tina Glisovic-Aplenc, Theresa Ryan, Kimberly Veliz, Haley Newman, Gerald Wertheim, Hamid Bassiri, Annette Vu, Michael Hogarty, Carl H June, Stephan A. Grupp, Sarah K Tasian, Richard Aplenc, Saar Gill, David T. Teachey

Blood (2022) 140 (Supplement 1): 10285–10286.

https://doi.org/10.1182/blood-2022-167893

Published: 2022

Journal Articles

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Blood (2022) 140 (Supplement 1): 4612–4614.

https://doi.org/10.1182/blood-2022-162393

Published: 2022

Journal Articles

Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

Nils Wellhausen, Austin K Rennels, Stefanie Lesch, Sangya Agarwal, Brooke Charria, Grace Choi, Regina M Young, Christopher Garcia, Carl H June, Saar Gill

Blood (2022) 140 (Supplement 1): 862–864.

https://doi.org/10.1182/blood-2022-158684

Published: 2022

Journal Articles

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

Blood (2022) 139 (9): 1289–1301.

https://doi.org/10.1182/blood.2020008493

Published: 2022

Includes: Supplemental data

Journal Articles

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 253.

https://doi.org/10.1182/blood-2021-153945

Published: 2021

Journal Articles

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Regina M. Myers, Kaitlin Devine, Yimei Li, Sophie Lawrence, Allison Barz Leahy, Hongyan Liu, Lauren Vernau, Colleen Callahan, Diane Baniewicz, Stephan Kadauke, Regina McGuire, Margaret A Cameron, Amanda M. DiNofia, Susan R. Rheingold, Richard Aplenc, Carl H June, Stephan A. Grupp, Lisa Wray, Shannon L. Maude

Blood (2021) 138 (Supplement 1): 474.

https://doi.org/10.1182/blood-2021-147299

Published: 2021

Journal Articles

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Blood (2021) 138 (Supplement 1): 469.

https://doi.org/10.1182/blood-2021-153955

Published: 2021

Journal Articles

Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Marco Ruella, Mireia Uribe-Herranz, Silvia Beghi, Kalpana Parvathaneni, Nektarios Kostopoulos, Guido Ghilardi, Kimberly Amelsberg, Yong Gu Gu Lee, Raymone Pajarillo, Noelle V Frey, Simon F Lacey, Khatuna Gabunia, John Scholler, Elise A Chong, Carl H June, David L. Porter, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene

Blood (2021) 138 (Supplement 1): 163.

https://doi.org/10.1182/blood-2021-151093

Published: 2021

Journal Articles

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Blood (2021) 138 (Supplement 1): 166.

https://doi.org/10.1182/blood-2021-152664

Published: 2021

Journal Articles

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Blood (2021) 138 (Supplement 1): 167.

https://doi.org/10.1182/blood-2021-149477

Published: 2021

Journal Articles

Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients

Kalpana Parvathaneni, Kyabeth Toress-Rodriguez, Wenzhao Meng, James Knox, Xiaoming Xu, Daniela Weiskopf, Noelle V Frey, Eline Luning-Prak, Alfred L Garfall, Michael Betts, Wei-Ting Hwang, David L Porter, Carl H June, Ali Naji, Vijay Bhoj

Blood (2021) 138 (Supplement 1): 1757.

https://doi.org/10.1182/blood-2021-153730

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-136860

Published: 2020

Journal Articles

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

Qian Zhang, Elena J. Orlando, Hong Y. Wang, Agata M. Bogusz, Xiaobin Liu, Simon F. Lacey, Honore T. Strauser, Selene Nunez-Cruz, Reza Nejati, Paul Zhang, Sarah Brooks, Christopher Watt, J. Joseph Melenhorst, Carl H. June, Stephen J. Schuster, Mariusz A. Wasik

Blood (2020) 136 (17): 1980–1983.

https://doi.org/10.1182/blood.2020005123

Published: 2020

Includes: Supplemental data

Journal Articles

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson W. Katona, Kienan P. O’Dwyer, Don L. Siegel, Carl H. June, Xianxin Hua

Blood (2020) 135 (10): 713–723.

https://doi.org/10.1182/blood.2019002779

Published: 2020

Includes: Supplemental data

Journal Articles

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Jr, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar I. Gill

Blood (2020) 135 (7): 505–509.

https://doi.org/10.1182/blood.2019001859

Published: 2020

Includes: Supplemental data

Journal Articles

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Elise A. Chong, Bruce L. Levine, Stephan A. Grupp, Megan M. Davis, Don L. Siegel, Shannon L. Maude, Whitney L. Gladney, Noelle V. Frey, David L. Porter, Wei-Ting Hwang, Emeline R. Chong, Carl H. June, Stephen J. Schuster

Blood (2019) 134 (21): 1873–1875.

https://doi.org/10.1182/blood.2019002258

Published: 2019

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

NARROW

Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma

The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies

Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL

Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19

Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome

Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only